{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number of patients with at least one grade 3 or greater AE, regardless of attribution, will be reported.","groups":[{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> Carfilzomib: Given IV\\>\n\n\\> Daratumumab: Given IV\\>\n\n\\> Dexamethasone: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> Selinexor: Given PO","id":"OG000","title":"Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Patients With a Grade 3 or Greater Adverse Event","type":"SECONDARY","unitOfMeasure":"Participants"}